AS-Logic: Computing the Tipping Point in Asymptomatic Severe Aortic Stenosis

Authors

  • Niraj S Kumar University of Nottingham image/svg+xml
  • Ruhani Singh National Medical Research Association, UK

DOI:

https://doi.org/10.66040/4mykv756

Keywords:

aortic stenosis, meta-analysis, randomised trials, transcatheter aortic valve replacement, TAVR, surgical aortic valve replacement, SAVR, evidence synthesis, early intervention, cardiac surgery, interventional cardiology

Abstract

Management of asymptomatic severe aortic stenosis (AS) has shifted from traditional “watchful waiting” to a contested debate over early intervention. Early surgical trials (RECOVERY, AVATAR) suggest benefit from prompt aortic valve replacement, whereas EVOLVED showed no advantage when intervention was triggered by myocardial fibrosis, and EARLY-TAVR demonstrated substantial benefit with transcatheter aortic valve replacement (TAVR). Pooling these small, heterogeneous trials with conventional random-effects meta-analysis risks overstating certainty. We developed AS-Logic, a single-page HTML/JavaScript evidence-synthesis dashboard that bakes conservative assumptions into the analysis. The tool implements Hartung–Knapp–Sidik–Jonkman (HKSJ) random-effects meta-analysis, explicit prediction intervals, and an interactive “fibrosis toggle” that separates anatomically severe from fibrosis-selected populations. AS-Logic allows clinicians to explore how pooled hazard ratios, heterogeneity, prediction intervals and number-needed-to-treat change when EVOLVED is included or excluded and when TAVR and surgery are analysed together or separately. In doing so, it reframes the asymptomatic AS controversy from a simple “early versus conservative” question into a more nuanced tipping point defined by modality and patient selection.

References

1. Tsampasian V, Verma A, Bhogal S, Byrne J, Narayan P. Management of asymptomatic severe aortic stenosis. Open Heart. 2022;9(1):e001982. PMID: 35640965.

2. Kang DH, Park SJ, Lee SA, et al. Early surgery or conservative care for asymptomatic aortic stenosis. N Engl J Med. 2020;382(2):111-119. PMID: 31733181.

3. Banovic M, Putnik S, Penicka M, et al. Aortic valve replacement versus conservative treatment in asymptomatic severe aortic stenosis (AVATAR trial). Circulation. 2022;145(9):648-658. PMID: 34779220.

4. Loganath K, Craig NJ, Everett RJ, et al. Early intervention in patients with asymptomatic severe aortic stenosis and myocardial fibrosis (EVOLVED). JAMA. 2025;333(3):213-221. PMID: 39466640.

5. Généreux P, Schwartz A, Oldemeyer JB, et al. Transcatheter aortic-valve replacement for asymptomatic severe aortic stenosis (EARLY TAVR). N Engl J Med. 2025;392(3):217-227. PMID: 39466903.

6. IntHout J, Ioannidis JPA, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol. 2014;14:25. PMID: 24548571.

Published

2026-06-06 — Updated on 2026-06-16

Versions

Issue

Section

E468 Short Report

How to Cite

AS-Logic: Computing the Tipping Point in Asymptomatic Severe Aortic Stenosis. (2026). Synthēsis, 2(4). https://doi.org/10.66040/4mykv756 (Original work published 2026)

Similar Articles

11-20 of 75

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)